cagrisema cagrilintide semaglutide phase 3 obesity Cagrilintide–semaglutide (CagriSema) versus or in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, study Cagrilintide–semaglutide (CagriSema) as an add-on

Sample Meal Ideas for GLP-1 Users Breakfast might include Greek yogurt with berries or scrambled eggs with spinach

Who Benefits Most From GLP-1 Treatment and How to Set Realistic Expectations GLP-1 medications are indicated for adults with obesity (BMI 30) or overweight (BMI 27) with at least one weight-related condition (hypertension, type 2 diabetes, cardiovascular disease, or sleep apnea)

32.7% of participants taking 0.5mg and 36.4% of participants taking 1mg of Ozempic experienced gastrointestinal adverse reactions such as nausea, vomiting, and diarrhea

Wong, C., Lee, M

Patients should never ignore persistent or worsening symptoms or adjust their prescribed treatment on their own

Reconstitution: 2.0 mL per 5000 IU vial (2,500 IU/mL) for precise insulinsyringe measurements